Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value (Tables)

Fair Value (Tables)

9 Months Ended

Sep. 30, 2020

Schedule of financial assets measured at fair value on a recurring basis

Financial assets measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations (in thousands):


	Assets at Fair Value as of September 30, 2020
	Level 1		Level 2		Level 3		Total
Money market funds	$	17,625	$	—	$	—	$	17,625
U.S. treasury bills		—		23,297		—		23,297
Government-sponsored enterprise securities		—		18,451		—		18,451
Corporate bonds and commercial paper		—		11,947		—		11,947
Total	$	17,625	$	53,695	$	—	$	71,320


	Assets at Fair Value as of December 31, 2019
	Level 1		Level 2		Level 3		Total
Money market funds	$	7,457	$	—	$	—	$	7,457
U.S. treasury bills		—		12,539		—		12,539
Government-sponsored enterprise securities		—		19,017		—		19,017
Corporate bonds and commercial paper		—		55,694		—		55,694
Total	$	7,457	$	87,250	$	—	$	94,707